Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)

Bibliographic Details
Main Authors:	Hwi Seung Kim, Hong-Kyu Kim, Chang Hee Jung
Format:	Article
Language:	English
Published:	Korean Diabetes Association 2023-03-01
Series:	Diabetes & Metabolism Journal
Online Access:	http://e-dmj.org/upload/pdf/dmj-2023-0058.pdf

Similar Items

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
by: Eun Roh
Published: (2023-03-01)

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
by: Hwi Seung Kim, et al.
Published: (2023-01-01)

Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition (Diabetes Metab J 2023;47:784-95)
by: Ho Gyun Lee, et al.
Published: (2024-01-01)

Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition (Diabetes Metab J 2023;47:784-95)
by: Jae Hyun Bae
Published: (2024-01-01)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
by: Tzu-Yi Lin, et al.
Published: (2023-07-01)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
by: Jihee Ko, et al.
Published: (2023-07-01)

Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis ( 2023;47:356-65)
by: Hye Jun Kim, et al.
Published: (2023-09-01)

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
by: Da Hea Seo, et al.
Published: (2022-11-01)

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
by: Hong-Kyu Kim, et al.
Published: (2023-10-01)

Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis ( 2023;47:356-65)
by: Jung Hun Ohn
Published: (2023-09-01)

Recent advances in nonalcoholic fatty liver disease metabolomics
by: Hwi Young Kim
Published: (2021-10-01)

Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Min-Kyu Kang, et al.
Published: (2023-02-01)

Response: Eccentric Versus Concentric Exercises in Patients With Rheumatoid Arthritis and Rotator Cuff Tendinopathy: A Randomized Comparative Study ( 2023;47:26-35)
by: Mina Magdy Wahba, et al.
Published: (2024-02-01)

Association of Body Mass Index and Fracture Risk Varied by Affected Bones in Patients with Diabetes: A Nationwide Cohort Study ( 2023;47:242-54)
by: Se-Won Lee, et al.
Published: (2023-05-01)

Association of Body Mass Index and Fracture Risk Varied by Affected Bones in Patients with Diabetes: A Nationwide Cohort Study ( 2023;47:242-54)
by: So Young Park
Published: (2023-05-01)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
by: Waseem Amjad, et al.
Published: (2023-08-01)

Correlation between Myosteatosis and Liver Fibrosis among Patients with Non Alcoholic Fatty Liver Disease: A Cross-Sectional Study
by: Samhita Ankala, et al.
Published: (2023-11-01)

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
by: Ji Hye Huh
Published: (2022-11-01)

Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
by: Min Chul Kim, et al.
Published: (2020-01-01)

Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
by: Gwyneth Shook Ting Soon, et al.
Published: (2021-01-01)

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
by: Jung Hwan Yu, et al.
Published: (2023-02-01)

Noninvasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease
by: Yu.M. Stepanov, et al.
Published: (2017-09-01)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)
by: Mi-kyung Kim
Published: (2021-11-01)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)
by: Eugene Han, et al.
Published: (2021-11-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
by: D.N. Amarapurkar, et al.
Published: (2006-01-01)

Role of mast cells in the pathogenesis of liver fibrosis in nonalcoholic fatty liver disease
by: Ewa Lewandowska, et al.
Published: (2020-05-01)

NONALCOHOLIC FATTY LIVER DISEASE: COMORBIDITIES, CLINICAL SIGNIFICANCE AND EVALUATION OF LIVER FIBROSIS
by: D. V. Marshalko, et al.
Published: (2018-02-01)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
by: Taeang Arai, et al.
Published: (2021-08-01)

Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease
by: Ashley Cast, et al.
Published: (2019-08-01)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
by: Stefano Ciardullo, et al.
Published: (2021-07-01)

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
by: Gwyneth Soon, et al.
Published: (2021-01-01)

Expression of the Long Noncoding RNA GAS5 Correlates with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Man-Hoon Han, et al.
Published: (2020-05-01)

Type IV collagen as marker of fibrosis in nonalcoholic liver disease
by: Alvina
Published: (2010-08-01)

Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
by: Hyuktae Kwon
Published: (2020-03-01)

Response: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
by: Goh Eun Chung, et al.
Published: (2020-03-01)

Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
by: Chan-Hee Jung
Published: (2020-06-01)

Transaminases and gamma glutamyl transpeptidase for detecting nonalcoholic steatohepatitis and fibrosis in nonalcoholic fatty liver disease
by: Shahinul Alam, et al.
Published: (2016-07-01)

The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation
by: Zoltan Czigany, et al.
Published: (2021-04-01)

The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: Chia-Yen Dai, et al.
Published: (2022-06-01)

Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease
by: Yoshiko Terasaka, et al.
Published: (2023-07-01)